3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Glioblastoma
2
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Renal Insufficiency
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Melanoma
1
Lung Neoplasms
1
Liver Failure
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Rituximab
9
venetoclax
7
ibrutinib
7
Cyclophosphamide
7
Mycophenolic Acid
5
fludarabine phosphate
4
Whole-Body Irradiation
4
Sirolimus
4
zanubrutinib
3
pirtobrutinib
3
Peripheral Blood Stem Cell Transplantation
3
Dexamethasone
3
Cyclosporine
3
ixazomib
2
fludarabine
2
carfilzomib
2
acalabrutinib
2
Tacrolimus
2
Melphalan
2
Etoposide
2
Cyclosporins
2
Calcium Dobesilate
2
CT-P10
2
Busulfan
2
Bendamustine Hydrochloride
2
talquetamab
1
pembrolizumab
1
loncastuximab tesirine
1
brexucabtagene autoleucel
1
Vincristine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
veliparib
×
90 days
×
Clear all
No trials found.